Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revisionLast revisionBoth sides next revision | ||
mrepo:topics:biologicalsamples [16/05/2018 @ 11:08] – adammoore | mrepo:topics:biologicalsamples [03/10/2018 @ 16:42] – nmpo | ||
---|---|---|---|
Line 17: | Line 17: | ||
Stored biological samples available from [[questionnaires: | Stored biological samples available from [[questionnaires: | ||
lithium heparin plasma, cell lines, and DNA. The following tables list the current data available from these samples.\\ \\ | lithium heparin plasma, cell lines, and DNA. The following tables list the current data available from these samples.\\ \\ | ||
- | {{mrepo:bloods_1999.jpg? | + | < |
+ | <table x:str="" | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 3ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 6ml ACD tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p> ECACC </ | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 4ml Lithium heparin tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 3ml EDTA tube</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | |||
+ | |||
+ | |||
---- | ---- | ||
\\ | \\ | ||
Line 23: | Line 157: | ||
__Blood__ | __Blood__ | ||
- | At 60-64 years, fasting blood, saliva and overnight urine samples were collected, either in Clinical Research Facilities or at home. The volume of blood and processing protocol was designed to provide aliquots suitable for the analysis of biomarkers identified by LHA and its collaborators to be relevant to ageing and health. | + | At 60-64 years, fasting blood, saliva and overnight urine samples were collected, either in Clinical Research Facilities or at home. The volume of blood and processing protocol was designed to provide aliquots suitable for the analysis of biomarkers identified by LHA and its collaborators to be relevant to ageing and health. The collection and storage of the biological samples was organised by MRC Human Nutrition Research (HNR) in Cambridge. |
Up to 55ml of fasting blood was obtained from the study members, with a smaller volume being collected at remote home visits because the time to processing was too long to maintain the integrity of some analytes. | Up to 55ml of fasting blood was obtained from the study members, with a smaller volume being collected at remote home visits because the time to processing was too long to maintain the integrity of some analytes. | ||
DNA extractions were conducted on the EDTA tube used in the first round blood haematology analysis. Samples for lymphoid cell line transformations were originally collected in 1999; for those that did not previously provide a sample, one was collected in 2006-10. \\ \\ | DNA extractions were conducted on the EDTA tube used in the first round blood haematology analysis. Samples for lymphoid cell line transformations were originally collected in 1999; for those that did not previously provide a sample, one was collected in 2006-10. \\ \\ | ||
- | {{mrepo:bloods_0610.jpg? | + | |
+ | < | ||
+ | <table x:str="" | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | <td class=" | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml EDTA tube (EN1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml EDTA tube (EN2)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> None as sample was sent for HbA1c and red cell folate analysis <p> | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 2.7ml Fluoride tube (FL N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | < | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Lithium heparin tube (trace metal) (LH N1)</ | ||
+ | </ | ||
+ | < | ||
+ | <p>LH INS for insulin; LH VITC for vitamin C analysis</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>LH B1, LH C1, LH C2, LH C3 </ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 8.5ml CPDA (for cell lines if required) (CP N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Serum tube (SE N1)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> Samples from the two serum tubes were used to produce priority aliquots SE A1 for TFTs and SE A2 for analyses at NHR</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>SE B1, SE C1, SE C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 7.5ml Serum tube (SE N2)</ | ||
+ | </ | ||
+ | < | ||
+ | <p> Samples from the two serum tubes were used to produce priority aliquots SE A1 for TFTs and SE A2 for analyses at NHR</ | ||
+ | </ | ||
+ | <td > | ||
+ | <p>SE B1, SE C1, SE C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 4.9ml EDTA tube (E N3)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>E B1, E C1</ | ||
+ | </ | ||
+ | </ | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>1 x 10ml Citrate tube (CI N1)</ | ||
+ | </ | ||
+ | < | ||
+ | < | ||
+ | </ | ||
+ | <td > | ||
+ | <p>CI B1, CI C1, CI C2</ | ||
+ | </ | ||
+ | </ | ||
+ | |||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | *Blood tubes/ | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
\\ \\ | \\ \\ | ||
__Urine__ | __Urine__ | ||
- | Overnight urine was collected, however the protocol for processing and storing the samples was changed during the data collection, resulting in a different number of aliquots being collected compared to the later period. | + | Overnight urine was collected, however the protocol for processing and storing the samples was changed during the data collection, resulting in a different number of aliquots being collected compared to the later period. The original protocol was inappropriate for albumin measurement as they should have been centrifuged; |
\\ \\ | \\ \\ | ||
__Saliva__ | __Saliva__ | ||
- | The collection of saliva samples only began after a pilot study, and the protocol consisted of one sample collected on the day of the clinical assessment and a further three at home. HNR received all of these first samples, but for about 68 people (3%), no further samples were received. | + | The collection of saliva samples only began after a pilot study, and the protocol consisted of one sample collected on the day of the clinical assessment and a further three at home. HNR received all of these first samples, but for about 68 people (3%) no further samples were received. The collected saliva samples were sent to Germany for cortisol analysis before being returned to HNR. |
---- | ---- | ||
Line 42: | Line 337: | ||
=== Age 68-70=== | === Age 68-70=== | ||
- | \\ | + | At 68-70 years non-fasting blood samples were collected at a home visit by research nurses. |
+ | |||
+ | A number of assays have been undertaken and the remaining aliquots of EDTA, citrate plasma and serum are stored at the Bristol Bioresource Laboratories. | ||
+ | < | ||
+ | <table x: | ||
+ | < | ||
+ | <tr style=" | ||
+ | <td class=" | ||
+ | < | ||
+ | </td> | ||
+ | <td class=" | ||
+ | < | ||
+ | </td> | ||
+ | <td class=" | ||
+ | < | ||
+ | </td> | ||
+ | <td class=" | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 2.7ml citrate</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | <p> Cholesterol, | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 5ml Serum</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 4ml EDTA</ | ||
+ | </td> | ||
+ | <td> | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr > | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | <td > | ||
+ | <p>1 x 4ml EDTA </p> | ||
+ | </td> | ||
+ | <td> | ||
+ | <p> None</ | ||
+ | </td> | ||
+ | <td > | ||
+ | < | ||
+ | </td> | ||
+ | </tr> | ||
+ | </ | ||
+ | </ | ||
+ | </ | ||
+ | ---- | ||
+ | \\ | ||
+ | ^ | ||
- | ^ Table 2 - Biomarkers available at age 53 and 63. Biomarkers highlighted in bold are not present in other UK birth cohorts | + | ^System |
- | ^System | + | |**Metabolic** |
- | |**Metabolic** | + | | ::: |
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |Cholesterol, |
- | | ::: |Triglycerides | + | | ::: |Triglycerides |
- | | ::: |Glycated Haemoglobin, | + | | ::: |
- | | ::: | + | |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |Glycated Haemoglobin, |
|**Diet & Iron Markers**| | |**Diet & Iron Markers**| | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
|**Inflammatory** | |**Inflammatory** | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
Line 85: | Line 488: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
| ::: | | ::: | ||
| ::: | | ::: | ||
| ::: | | ::: | ||
- | | ::: | + | | ::: |
- | | ::: | + | | ::: |
- | |**Neuro-Endocrine** | + | |**Neuro-Endocrine** |
- | | ::: |Insulin Growth Factor 1, IGF-1 (nmol/L) |DHEAS (umol/ | + | | ::: |DHEAS (umol/L) |DHEAS (umol/ |
- | | ::: |Sex hormone binding globulin, SHBG (nmol/ | + | | ::: |Insulin Growth Factor 1, IGF-1 (nmol/ |
- | | ::: |Testosterone (nmol/ | + | | ::: |
| ::: | | ::: | ||
- | | ::: | + | | ::: |Sex hormone binding globulin, SHBG (nmol/ |
- | | ::: | + | | ::: |Testosterone (nmol/ |
| ::: | | ::: | ||
| ::: | | ::: | ||
Line 131: | Line 534: | ||
- | |||
- | ---- | ||
- | |||
- | === DNA === | ||
- | |||
- | Around 2,900 study members have given consent for DNA to be extracted | ||
- | from blood and / or buccal samples and LHA was given ethical approval in | ||
- | 2007 to use these samples for genetic studies of lifelong health and | ||
- | ageing. \\ | ||
- | Genetic studies help us to elucidate biological mechanisms of | ||
- | ageing and understand why people with similar life experiences age | ||
- | differently. | ||
- | |||
- | The NSHD DNA Repository supports high calibre studies of human health | ||
- | and disease that make the best use of the genetic resource in | ||
- | conjunction with the existing life course data. Dr Andrew Wong | ||
- | coordinates the genetic research of the NSHD and is responsible for | ||
- | the safe storage and efficient use of the samples, which are managed | ||
- | by Source BioScience. | ||
- | |||
- | {{mrepo: | ||
- | available. | ||